Myeloid Growth Factor Therapy for Prophylaxis of Febrile Neutropenia in Non-Myeloid Malignancies: Appropriate Doses and Schedules

Crawford J, Althaus B, Armitage J et al.. The NCCN Myeloid Growth Factors Clinical Practice Guidelines in Oncology, version 1, 2006. Available at: http://www.nccn.org/professionals/physician_glas/PDF/myeloid_growth.pdf. Accessed December 5, 2006.

CrawfordJAlthausBArmitageJ. The NCCN Myeloid Growth Factors Clinical Practice Guidelines in Oncology, version 1, 2006. Available at: http://www.nccn.org/professionals/physician_glas/PDF/myeloid_growth.pdf. Accessed December 5, 2006. )| false
• Search Google Scholar
• Export Citation

Neupogen (filgrastim) [prescribing information]. Thousand Oaks, CA: Amgen; 2004.

Neupogen (filgrastim) [prescribing information]. Thousand Oaks, CA: Amgen; 2004. )| false
• Search Google Scholar
• Export Citation

Leukine (sargramostim) [prescribing information]. Seattle, WA: Berlex; 2004.

Leukine (sargramostim) [prescribing information]. Seattle, WA: Berlex; 2004. )| false
• Search Google Scholar
• Export Citation

Smith TJ, Khatcheressian J, Lyman GH et al.. Update for recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187–3205.

SmithTJKhatcheressianJLymanGH. Update for recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187–3205. )| false
• Search Google Scholar
• Export Citation

Neulasta (pegfilgrastim) [prescribing information]. Thousand Oaks, CA: Amgen; 2004.

Neulasta (pegfilgrastim) [prescribing information]. Thousand Oaks, CA: Amgen; 2004. )| false
• Search Google Scholar
• Export Citation

Johnston E, Crawford J, Blackwell S et al.. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:2522–2528.

JohnstonECrawfordJBlackwellS. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:2522–2528. )| false
• Search Google Scholar
• Export Citation

Aapro MS, Cameron DA, Pettengell R et al.. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumors. Eur J Cancer 2006;42:2433–2453.

AaproMSCameronDAPettengellR. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumors. Eur J Cancer 2006;42:2433–2453. )| false
• Search Google Scholar
• Export Citation

Scott SD, Chrischilles EA, Link BK et al.. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy. J Manag Care Pharm 2003;9(2 suppl):15–21.

ScottSDChrischillesEALinkBK. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy. J Manag Care Pharm 2003;9(2 suppl):15–21. )| false
• Search Google Scholar
• Export Citation

Weycker D, Hackett J, Edelsberg JS et al.. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 2006;40:402–407.

WeyckerDHackettJEdelsbergJS. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 2006;40:402–407. )| false
• Search Google Scholar
• Export Citation

Citron ML, Berry DA, Cirrincione C et al.. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431–1439.

CitronMLBerryDACirrincioneC. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431–1439. )| false
• Search Google Scholar
• Export Citation

Papaldo P, Lopez M, Marolla P et al.. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 2005;23:6908–6918.

PapaldoPLopezMMarollaP. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 2005;23:6908–6918. )| false
• Search Google Scholar
• Export Citation

Djulbegovic B, Frohlich A, Bennett CL. Acting on imperfect evidence: how much regret are we ready to accept? J Clin Oncol 2005;23:6822–6825.

DjulbegovicBFrohlichABennettCL. Acting on imperfect evidence: how much regret are we ready to accept? J Clin Oncol 2005;23:6822–6825. )| false
• Search Google Scholar
• Export Citation

Yang BB, Hill RL, Hollifield AM et al.. Pegfilgrastim serum concentrations on the twelfth day after dosing are unlikely to stimulate granulopoiesis: a retrospective analysis of 6 clinical trials in a variety of cancer populations. Poster presented at the 45th Annual Meeting of the American Society of Hematology; December 6–9, 2003; San Diego, California. Abstract 1918.

YangBBHillRLHollifieldAM. Pegfilgrastim serum concentrations on the twelfth day after dosing are unlikely to stimulate granulopoiesis: a retrospective analysis of 6 clinical trials in a variety of cancer populations. Poster presented at the 45th Annual Meeting of the American Society of Hematology; December 6–9, 2003; San Diego, California. Abstract 1918. )| false
• Search Google Scholar
• Export Citation

Burstein HJ, Parker LM, Keshaviah A et al.. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 2005;23:8340–8347.

BursteinHJParkerLMKeshaviahA. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 2005;23:8340–8347. )| false
• Search Google Scholar
• Export Citation

Wolff AC, Jones RJ, Davidson NE et al.. Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support (letter). J Clin Oncol 2006;24:2392–2394.

WolffACJonesRJDavidsonNE. Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support (letter). J Clin Oncol 2006;24:2392–2394. )| false
• Search Google Scholar
• Export Citation

Brusamolino E, Rusconi C, Montalbetti L et al.. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006;91:496–502.

BrusamolinoERusconiCMontalbettiL. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006;91:496–502. )| false
• Search Google Scholar
• Export Citation

Meropol NJ, Miller LL, Korn EL et al.. Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 1992;84:1201–1203.

MeropolNJMillerLLKornEL. Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 1992;84:1201–1203. )| false
• Search Google Scholar
• Export Citation

Rowinsky EK, Grochow LB, Sartorius SE et al.. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol 1996;14:1224–1235.

RowinskyEKGrochowLBSartoriusSE. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol 1996;14:1224–1235. )| false
• Search Google Scholar
• Export Citation

Petros WP, Crawford J. Safety of concomitant use of granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor with cytotoxic chemotherapy agents. Curr Opin Hematol 1997;4:213–216.

PetrosWPCrawfordJ. Safety of concomitant use of granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor with cytotoxic chemotherapy agents. Curr Opin Hematol 1997;4:213–216. )| false
• Search Google Scholar
• Export Citation

Weiss AJ, Lackman RD. Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor: advantages and limitations. Am J Clin Oncol 1997;20:63–68.

WeissAJLackmanRD. Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor: advantages and limitations. Am J Clin Oncol 1997;20:63–68. )| false
• Search Google Scholar
• Export Citation

Weiss AJ, Sabol J, Lackman RD. Concurrent administration of vinorelbine with recombinant human granulocyte colony-stimulating factor: an effective method of increasing dose intensity. Am J Clin Oncol 1999;22:38–41.

WeissAJSabolJLackmanRD. Concurrent administration of vinorelbine with recombinant human granulocyte colony-stimulating factor: an effective method of increasing dose intensity. Am J Clin Oncol 1999;22:38–41. )| false
• Search Google Scholar
• Export Citation

Livingston RB, Ellis GK, Gralow JR et al.. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997;15:1395–1400.

LivingstonRBEllisGKGralowJR. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997;15:1395–1400. )| false
• Search Google Scholar
• Export Citation

Vance KT, Carpenter J. Same day administration of pegfilgrastim with dose dense doxorubicin in early breast cancer patients [abstract]. J Clin Oncol 2006;24(suppl 1):45s. Abstract 671.

VanceKTCarpenterJ. Same day administration of pegfilgrastim with dose dense doxorubicin in early breast cancer patients [abstract]. J Clin Oncol 2006;24(suppl 1):45s. Abstract 671. )| false
• Search Google Scholar
• Export Citation

Lokich J. Same day pegfilgrastim and chemotherapy. Cancer Invest 2005;23:573–576.

LokichJ. Same day pegfilgrastim and chemotherapy. Cancer Invest 2005;23:573–576. )| false
• Search Google Scholar
• Export Citation

Hoffmann PS. Administration of pegfilgrastim on the same day or next day of chemotherapy [abstract]. J Clin Oncol 2005;23(suppl 1):763s. Abstract 8137.

HoffmannPS. Administration of pegfilgrastim on the same day or next day of chemotherapy [abstract]. J Clin Oncol 2005;23(suppl 1):763s. Abstract 8137. )| false
• Search Google Scholar
• Export Citation

Belani CP, Ramalingam A, Al-Janadi E et al.. A randomized double-blind phase II study to evaluate same-day vs next-day administration of pegfilgrastim with carboplatin and docetaxel in patients with NSCLC [abstract]. J Clin Oncol 2006;24(suppl 1):391s. Abstract 7110.

BelaniCPRamalingamAAl-JanadiE. A randomized double-blind phase II study to evaluate same-day vs next-day administration of pegfilgrastim with carboplatin and docetaxel in patients with NSCLC [abstract]. J Clin Oncol 2006;24(suppl 1):391s. Abstract 7110. )| false
• Search Google Scholar
• Export Citation

Kaufman PA, Paroly W, Rinaldi D et al.. Randomized, double-blind, phase 2 study evaluating same-day vs next-day administration of pegfilgrastim with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with early stage and advanced breast cancer [abstract]. Breast Cancer Res Treat 2004;88. Abstract 1054.

KaufmanPAParolyWRinaldiD. Randomized, double-blind, phase 2 study evaluating same-day vs next-day administration of pegfilgrastim with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with early stage and advanced breast cancer [abstract]. Breast Cancer Res Treat 2004;88. Abstract 1054. )| false
• Search Google Scholar
• Export Citation

Martin M, Lluch A, Segui MA et al.. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006;17:1205–1212.

MartinMLluchASeguiMA. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006;17:1205–1212. )| false
• Search Google Scholar
• Export Citation

Yardley DA, Greco FA, Burris HA et al.. Day 1 pegfilgrastim with dose dense adjuvant chemotherapy: amelioration of docetaxel neutropenia but not that of doxorubicin/cyclophosphamide. Results from a Sarah Cannon Research Institute pilot study [abstract]. J Clin Oncol 2005;23(suppl 1):65s. Abstract 749.

YardleyDAGrecoFABurrisHA. Day 1 pegfilgrastim with dose dense adjuvant chemotherapy: amelioration of docetaxel neutropenia but not that of doxorubicin/cyclophosphamide. Results from a Sarah Cannon Research Institute pilot study [abstract]. J Clin Oncol 2005;23(suppl 1):65s. Abstract 749. )| false
• Search Google Scholar
• Export Citation

Saven A, Schwartzberg L, Kaywin P et al.. Randomized, double-blind, phase 2 study evaluating same-day vs. next-day administration of pegfilgrastim with R-CHOP in non-Hodgkin's lymphoma patients [abstract]. J Clin Oncol 2006;24(suppl 1):439s. Abstract 7570.

SavenASchwartzbergLKaywinP. Randomized, double-blind, phase 2 study evaluating same-day vs. next-day administration of pegfilgrastim with R-CHOP in non-Hodgkin's lymphoma patients [abstract]. J Clin Oncol 2006;24(suppl 1):439s. Abstract 7570. )| false
• Search Google Scholar
• Export Citation

Lokich J. Same day pegfilgrastim and CHOP chemotherapy for non-Hodgkin's lymphoma. Am J Clin Oncol 2006;29:361–363.

LokichJ. Same day pegfilgrastim and CHOP chemotherapy for non-Hodgkin's lymphoma. Am J Clin Oncol 2006;29:361–363. )| false
• Search Google Scholar
• Export Citation